

Supplementary information

Three-dimensional Printed 5-Fluorouracil Eluting Polyurethane Stents for the Treatment of Oesophageal Cancers

Paris Fouladian¹, Jarrod Kohlhagen², Mohammad Arafat¹, Franklin Afinjuomo¹, Nathan Workman², Ahmad Y Abuhelwa³, Yunmei Song¹, Sanjay Garg 1,^{*}, Anton Blencowe^{2,*}

¹ Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

² Applied Chemistry and Translational Biomaterials (ACTB) group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia

³ Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park 5042, SA, Australia.

* Corresponding Authors. Email: sanjay.garg@unisa.edu.au; anton.blencowe@unisa.edu.au




Figure S1. Scanning electron microscopy (SEM) image of 5-FU powder used in the manufacture of the 3D printed, drug-eluting stents.




Figure S2. *In vitro* release data fitted to Higuchi, first order, zero-order, Hixon and Kors-Peppas release kinetics models.

Table S1. Physical stability parameters of 5-FU loaded stents.

| Storage condition | Initial | | After 3 months | |
|-------------------|--------------|----------------|----------------|----------------|
| | Weight (mg) | Thickness (mm) | Weight (mg) | Thickness (mm) |
| 25°C | 20.80 ± 0.05 | 0.80 ± 0.02 | 20.84 ± 0.05 | 0.81 ± 0.02 |
| 25°C/65% RH | 20.83 ± 0.10 | 0.80 ± 0.02 | 20.90 ± 0.08 | 0.81 ± 0.02 |
| 40°C/75%RH | 20.85 ± 0.07 | 0.80 ± 0.08 | 20.92 ± 0.03 | 0.81 ± 0.07 |